Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2013

AstraZeneca, Janssen to Promote Novel Prostate Cancer Treatment in Japan

  • AstraZeneca entered an agreement with Janssen Pharmaceuticals K.K. in Japan to co-promote abiraterone acetate, an oral therapy for the treatment of patients with prostate cancer. Janssen Pharmaceuticals K.K. in July submitted a marketing approval application for abiraterone acetate to the Japanese Ministry of Health, Labour and Welfare for the treatment of the deadly disease.

    Abiraterone acetate, otherwise known as Zytiga®, is a CYP17-inhibitor that inhibits the key enzyme that modulates the production of androgens from all sources in the body, which can treat prostate cancer by helping to lower the level of androgens available to prostate cancer cells. It was approved in the U.S. in April 2011 and in the EU in September of the same year for patients with metastatic castration-resistant prostate cancer in combination with prednisone before and after treatment with docetaxel.

    AZ notes that the main treatment option currently available to patients in Japan is medical castration.

    "Abiraterone acetate is a great addition to our existing portfolio of leading cancer treatments, with real potential to address an important and growing patient need," said Marc Dunoyer, AZ's evp, global products and portfolio strategy, in a statement. "This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »